Life Sciences Archive » August, 2020

Life Sciences - August, 2020

388 articles

• Trump's New Nursing-Home Tests Fuel 'Herd Immunity' Debate
• Gannett Escapes $500M COVID-19 Story Libel Suit, For Now
• Bio-Rad Gets 10X Genomics' Antitrust Claims Trimmed
• DOD Investigating Moderna's Vaccine Patents
• Neb. Sheriff Sues To Block State's Medical Pot Ballot Measure
• AbbVie Points 3rd Circ. To School Board Ruling In FTC Case
• Advancing Racial Justice In The Legal Industry And Beyond
• In Their Own Words: Being Black In BigLaw
• These Law Firms Have The Most Diverse Equity Partnerships
• How Law Firms Can Hire And Retain More Black Attorneys
• How COVID-19 May Forever Alter Work Life For Disabled Attys
• BigLaw Cannot Reap Diversity Rewards Without Inclusion
• Ideas For Closing BigLaw's Diversity Gap
• Diversity Snapshot: As Told By Black Law Firm Leaders
• BigLaw Needs More Underrepresented Attorneys As Leaders
• Boehringer Hits Sun Pharma With Suit Over Diabetes Generic
• Perrigo Faces Patent Suit Over Bausch's Psoriasis Lotion
• Judges Mull Whether Word 'Random' Kills Bayer Patent Win
• Ex-Indivior Exec Inks Plea Deal In Suboxone Opioid Case
• Gov't Contracts Of The Month: Vaccines, Space, AI Research
• Withers Continues To Grow Arbitration Practice In Singapore
• Nestle To Buy $2.6B Peanut Allergy Drug Developer
• HHS Lab Test Rule's Likely Impact During And After COVID-19
• Excess Insurer Owes Pfizer Coverage For Securities MDL
• Biopharma Co. Trevena Must Face Investors' Stock-Drop Suit
• States Urge High Court To Revive FDA's Abortion Pill Rules
• Vi-Jon Wants Hand Sanitizer False Ad Suit Wiped Out
• Law360's Diversity Snapshot: What You Need To Know
• One Year In, Mansfield Rule Is Boosting In-House Diversity
• Diversity Work Doesn't Have To Be Reserved For Partners
• Law360 Diversity Snapshot: How Does Your Firm Measure Up?
• Why 2020 Could Be A Pivotal Year For Diversity At Firms
• Fed. Circ. Won't Revive Pfizer's Fungus Treatment Patents
• Theranos Ex-COO Wants Latest Indictments Dismissed
• Biz 'Relies On Arb Clauses,' Justices Told In Dental Row
• UVA Researcher From China Stole Trade Secrets, Feds Say
• Activists Say Moderna Hid Gov't Support For Vaccine Patents
• Biotech Co. Says Ex-Worker Violated Trade Secrets Deal
• Pa. Sales Rep Says He Was Fired Over Medical Marijuana Use
• FCC Rejects Challenge To ViSalus Robocall Waiver
• Nebraska Medical Pot Proposal Beats '11th Hour' Challenge
• Judge Won't Rethink Sanctioning Atty, Co. In Shire IP Dispute
• Feds Sign $760M Deal For Abbott's Rapid COVID-19 Tests
• Brandt Urges Pause In BIPA Suit Until Appellate Rulings
• Sens. Want Nursing Home Probe Over Hydroxychloroquine
• IP Atty Gets Damages Slashed In Fight With Drug Pump Cos.
• SF Says Drug Cos. Are Liable For City Damage In Opioid Case
• Hologic Gets NovaSure Patent Judgment Bumped Up To $7M
• Seattle Bashes Bayer's $650M PCB Deals As A 'Pittance'
• Taxation With Representation: Paul Weiss, Simpson, Skadden
• IP Hires: Haynes & Boone, Barnes & Thornburg​​​​​​​, White & Case
• Cannabis Cos. Can't Ignore TCPA Compliance
• Lone Star Laterals: Munsch Hardt, King & Spalding
• B. Braun Medical Hit With ERISA Suit Over 401(k) Costs
• Hagens Berman Must Face Legal Malpractice Suit In Pa.
• Bayer's $10B Roundup Deal Teeters As Victims' Attys Cry Foul
• Fla. Regulator Clears Way For Medical Marijuana Edibles
• Melinta Rips Investor Challenge To Its Confirmed Ch. 11 Plan
• Nature's Way Ginkgo Pill Buyers Reach $3.4M False Ad Deal
• Medical Pot Exec Shared Trade Secrets With Rivals, Suit Says
• Shuttered Abbott Unit Beats Whistleblower's FCA Suit
• No Constitutional Right To Pot Licenses, Fla. Tells 11th Circ.
• Lab Accused Of Sending Junk Faxes For Its COVID-19 Testing
• Baxalta's IP Suit Over Genentech Blood Drug Gets New Life
• Pa. Avoiding Discovery In Price-Fixing Case, Drugmakers Say
• 4 Opportunities For Mediators To Settle Big-Dollar Cases
• Farmers Group Sues Monsanto To Get Roundup Off Shelves
• Another Pradaxa Labeling Suit Tossed In Connecticut
• COVID-19 Vaccine May Pose New Challenges For Employers
• Lantus Buyers Demand Info On More Sanofi Injector Patents
• Justices Told False Ad Cases Don't Require 'Actual Injury'
• Amgen Blasts Sandoz's En Banc Bid In Enbrel Patent Fight
• Pharma Co. Otsuka Buys Bankrupt Smart-Pill Maker For $15M
• Pharmacies Torch 'Unprecedented' Ruling On Opioid Duties
• Revive Abortion Drug Rules Despite Virus, FDA Tells Justices
• 1st Circ. Affirms New Lead Plaintiff Can't Save Biotech Suit
• Minn. Pushes Back On Drug Cos.' Bid To Kill Insulin RICO Suit
• The Growing Challenges To Drug Cos.' Preemption Defense
• Fenwick Helps Cancer Biotech Freenome Raise $270M
• Okla. Pot Regulators Say Testing Lab Falsified Results
• Remote Proceedings Bring New Wrinkles For Court Records
• Teva Is 7th Drug Co. Charged In DOJ Price-Fixing Probe
• John Ashcroft Joins Team Fighting J&J To Keep $2B Talc Win
• Two More Settlements OK'd In Nevada Pot Licensing Snafu
• Ex-Pharma CEO Charged With Inside Trading Over Teva Deal
• Ex-DOJ Civil Chief, Back In BigLaw, Dishes On Hot FCA Topics
• Invisalign Maker Says Qualcomm Ruling Supports Escape Bid
• Goodwin Nabs Ex-HHS Atty From Bass Berry
• Senate Bill Would Give FDA Authority To Recall Drugs
• Dealing With Prior DOJ Health Investigations During COVID-19
• Latham, Simpson Shape $320M Cryogenic Services Merger
• Cross-Selling Strategies For Law Firms During Pandemic
• Coronavirus Regulations: A State-By-State Week In Review
• Baxter Wants Investor Suit Over Forex Accounting Tossed
• Del. Croda Plant Hit With Toxic Chemical Release Suit
• FCPA Enforcement, Compliance Trends During The Pandemic
• Paul Hastings Welcomes Back Partner After In-House Stint
• Court Looks To Streamline Dispute Between IQVIA And Veeva
• Biotech Co. Lied About COVID-19 Vaccine, Investors Say
• Dr. Reddy's Can Add Antitrust Allegations In Suboxone Row
• Gilead Says Law Firm's Ads Misrepresent HIV Drug Suit
• Regeneron Says Feds' Kickback Suit 'Defies Common Sense'
• PTAB Upholds Entirety Of 3 Narcan Patents
• Sun Pharma Unit Pays $21M To End Whistleblower Suit
• Colgate Retirees Win $300M Suit Over Benefit Calculation
• Cannabis Co. Attys Can't Practice In Okla., Shareholders Say
• Ariz. Schools Accuse E-Cig Cos. Of Deceptive Marketing
• Zetia Buyers Granted Cert. Despite Small Class Size
• Weil, Simpson Weld Medical Device Deal Worth Up To $825M
• Chancery Keeps AmerisourceBergen Drug Scheme Suit Alive
• Atty Media Interview Lessons From Trump's Axios Appearance
• 7th Circ. FCA Dismissal Ruling May Have Unintended Effects
• EPA Approves Long-Lasting Coronavirus Disinfectant In Texas
• 2 Firms Help Blackstone Strike $2.3B Deal For Takeda Unit
• SEC Says There's 'No Dispute' Biotech Brass Broke Law
• Drug Cos. Blocking 340B Meds Amid Pandemic, Hospitals Say
• AmerisourceBergen Board Looks To Ax Opioid Derivative Suit
• Mintz Picks Up Partner From Boies Schiller
• Ferring Gets Rival's Patents Scrapped In Zoom Trial Win
• 7th Circ. Told Class Objector Side Deals Ruling Creates Split
• Stryker Corp. Scores Trial Win In XL Insurance Coverage Suit
• Pharma Giants Tee Up Biologics Innovation Fight At Fed. Circ.
• COVID-19 IP Catch-Up: Hatch-Waxman, Vaccine Patents
• Medical Pot Co. Hires Ex-Vitamin Shoppe Atty To Be New GC
• US Should Not Confiscate Gilead's Remdesivir Patent
• Dental Distributor Says Antitrust Fight Must Be Arbitrated
• Ariz. Justices OK Measure To Legalize, Tax Pot For Nov. Ballot
• Berger Montague Drops Bankrupt Client In Lipitor Case
• Taxation With Representation: Cravath, Sullivan, Hogan
• Why Remote Depositions Are Likely Here To Stay
• Alcon Claims Lens.com Led It On 'Antitrust Wild Goose Chase'
• How USPTO Examiner Type Affects Patents: Part 4
• ITC Will Explore Supply Chain Issues For COVID-19 Goods
• Justices Told Fed. Circ. Wrongly OKs PTAB With New Findings
• DEA Proposes Rule For Regulating Hemp-Derived CBD
• 9th Circ. Backs Doctor Aide's Opioid Distribution Conviction
• Pharmacy Board Asks 6th Circ. To Block Opioid Rx Info
• Shkreli's Prison Comms Get Partial Protection From FTC
• 'Artful Pleading' Can't Save Surescripts Antitrust Suit
• 3rd Circ. Upholds Liberty's Win In Pharmacy's Painkiller Suit
• Womble Bond Nabs Ex-Buchanan Ingersoll Patent Litigator
• Hatch-Waxman Complaints Down Sharply During Pandemic
• Vitamin Retailer GNC Cleared To Solicit Votes On Ch. 11 Plan
• 7 Keys To Drafting Effective Legal Briefs
• Consultant Says Express Scripts 'Fabricating' Subpoena Fight
• Bayer Pays $1.6B To Settle Suits Over Essure Contraceptive
• Legend In Law: McKesson's Lori Schechter
• Fed. Circ. Revives Fee Bid In Gardasil Vaccine Act Case
• 4 Firms Vie To Lead Endo Investor Suit Over Opioid Crisis
• McKesson Gets FCA Suit Over Opioids Tossed, For Now
• 9th Circ. Denies DEA Bid To Dismiss Pot Rescheduling Case
• CVS Unit To Pay $4.5M To Settle Workers' Wage Suit
• Weighing The Virtual Courtroom Option In Civil Cases
• ITC Greenlights New Duties On Plastic From S. Korea, Oman
• Pair Of Life Science Cos. Raise Combined $247M In IPOs
• Real Estate Rumors: Bristol-Myers, WeWork, Kaizen
• Dow Dropped From Suit Linking Pesticides To Man's Cancer
• Actavis Inks Settlement In ADHD Drug Antitrust Suit
• Mylan Launches MS Drug Generic Amid Biogen Patent Fight
• Boies Schiller Owns Up To 'Mistake' With Opioid Suit Filing
• A USPTO Examination Policy Change You May Have Missed
• 7th Circ. Ruling Should Deter Class Objector Side Deals
• Cravath, Latham Steer J&J's $6.5B Momenta Buy
• J&J Asks South Carolina Justices To Split 2-Plaintiff Talc Trial
• Vivus Says Ch. 11 Plan Should Be OK'd Despite Opposition
• Mallinckrodt Must Face Infant Drug Pricing Claims
• 7th Circ. FCA Ruling Deepens Circuit Split On DOJ Dismissals
• Patients Want 2nd Circ. To Revive Pfizer Lipitor Suit
• NJ High Court Lets Pfizer Arbitrate Flight Attendant's Bias Suit
• 'Pharma Bro' Shkreli Suggests FTC Privacy Violation
• 5 Considerations For Enhancing SEC Disclosures Amid Crisis
• Surgeon, Distributor Cop To Kickbacks In Medical Fraud Case
• Attys Shouldn't Overlook Obligations To Potential Clients
• ICE Contractor Raps Whistleblower Fraud Report As Too Late
• Wash. Pot Co. Says Okla. Residency Rules Unconstitutional
• Endo Fights Class Cert. In Investors' Drug Price-Fixing Suit
• Lessons From Asbestos Can Help Resolve Opioid Liabilities
• 8 Firms Bid To Lead Stock Suit Over Revoked COVID-19 Test
• Purdue And Sacklers Caused $2.16T In Damage, NY Says
• Coronavirus Regulations: A State-By-State Week In Review
• Boehringer Strikes Deal To End DOL Pay Bias Probe
• How Pa. Cost-Of-Performance Decision May Affect Taxpayers
• Teva Paid $300M Kickbacks Through Copay Groups, Feds Say
• Cochlear To Pay $75M More If $268M Hearing IP Loss Stands
• Noncompete Considerations As Businesses Reopen, Rehire
• Novartis' MS Drug Patent Upheld And Generic Ruled Infringing
• Ex-NFL Player Takes Pot Legalization Fight To High Court
• Ex-DEA Agent Said Parts Of Opioid Report Taken From NY Suit
• Allergan Wins Bid To ID Breast Implant Patients In MDL
• DC Circ. Won't Revisit Eagle's Orphan Drug Win Against FDA
• Glumetza Buyers Get Cert. In Suit Over 800% Price Jump
• Zetia Buyers Win Recommendation For Class Cert.
• Lexicon Pharma Ditches Investor Suit Over Diabetes Drug
• Inflammatory Disease Biotech Kymera Launches $125M IPO
• CBD Co. Says Texas Pot Lobby Defamed It With Phony Report
• Speaker Program Limits Are Specific To Novartis Settlement
• Weil, Cooley Guide $3.7B Sanofi, Principia Biopharma Deal
• Medical Co. Sues Over Counterfeit Forehead Thermometers
• Strategies For Associates Seeking Jobs Amid Hiring Slump
• Biopharm Co. Leaders Accused Of 'Grossly Excessive' Pay
• IRS Urges 10th Circ. To Toss Pot Cos.' Tax Summons Fight
• Ex-Client Fights Hagens Berman Bid To End Malpractice Suit
• Merck Loses Appeal In NJ Zoning Change Challenge
• Can Big Damages Awards Affect Patent Valuation Dynamics?
• 1st COVID-19 Vaccine Patent Granted, Chinese Media Says
• ViSalus Can't Get $925M Robocall Damages Award Cut Down
• Ex-FDA Head Says He Didn't Ask NY Docs About Opioid Rx's
• McKesson's $178M Vaccine Deal Brings CDC Off The Bench
• Ex-Insys Sales Rep Evades Prison Over Opioid Bribe Ploy
• 9th Circ. Upholds $3.6M Award In Bard Filter Bellwether
• 3 Ways Life Sciences Cos. Can Protect Trade Secrets
• Constitutional Right To Prescribe Pot Hazy, 6th Circ. Says
• Cannabis Corruption Cases Ramp Up With FBI Scrutiny
• Mallinckrodt Must Face Antitrust Claims Over Seizure Drug
• 3M Inks Deal To End Mask Suit Against Amazon Vendor
• COVID-19 IP Catch-Up: All Eyes On Texas
• Belcher Tells Fed. Circ. Inequitable Conduct Order Implausible
• Fitness Co. Can't Sue Google Over Video Removal
• COVID-19 Vaccine Maker, Software Co. IPOs Raise $618M
• Safeguards Against Legal Malpractice Liability As Claims Rise
• UK Litigation Roundup: Here's What You Missed In London
• 4th Circ. Won't Pause Block On FDA Abortion Pill Limits
• ​​​​​​​3 Key Developments As COVID-19 Testing Czar Jabs Critics
• Customedia Tells Justices Fed. Circ. Arthrex Denial Is 'Unjust'
• Chancery Makes Juul Investor Seek Docs In Del., Not Calif.
• House Panel Seeks Answers On Virus Vaccine Campaign
• Irked Judge Says Boies Schiller Flouted Opioid MDL Order
• 6th Circ. Reinstates J&J Pelvic Mesh Suit
• McKesson, Cardinal Get Green Light For Opioid Bench Trial
• Juul Loses Bid To Arbitrate Canvassers' Wage Class Action
• Canadian Co. Says Hemp Dispute Can't Jump Between Courts
• Ill. Doctors Can't Dodge Sanctions Over Unserved Patent Suit
• Coronavirus Q&A: Akin Gump Partners On Virus Relief Probes
• FTC Says Shkreli's Prison Calls With Attorneys Not Privileged
• Proposed Vaccine Injury Rule Raises COVID-19 Concerns
• McDermott Nabs Pair Of IP Pros From Polsinelli
• AbbVie Calif. Settlement Guides Nurse Education Compliance
• Sorrento Investors Fight To Lead COVID-19 'Cure' Suit
• Cos. Must Heed FDA Warnings On Hand Sanitizers
• 3 Ways Law Firms Can Guard Diversity Gains During Crisis
• Qiagen Investors Shun Thermo Fisher's $12.5B Offer
• Kilpatrick Lures Texas Patent Pro From Vinson & Elkins
• Pharmacy Pays $3.5M To Settle DOJ Medicare Kickback Probe
• J&J Asks Mo. High Court To Overturn $2.1B Talc Ruling
• Pfizer Gets PTAB To Wipe Out Rest Of Sanofi's Lantus Patent
• SmileDirectClub Points To Ga. Dental Board Win In Ala. Appeal
• Nestle Hit With IP Suit Over Doc's Swallowing Test
• Resellers Say Drug Makers Erred In MDL Bellwether Claim
• 3 Firms Shape $384M Cancer Biopharma Co. Take-Private Deal
• Colgate Fights Retirees' Quick Win Bid In ERISA Class Action
• SoftBank-Backed Fortress SPAC Leads 2 IPOs Totaling $405M
• Jones Day Partner Up For Calif. Seat Lists Nearly $2M Assets
• BGI Genomics Can Develop DNA Tech During Patent Appeal
• Money Moves: Alston & Bird, Norton Rose, Saxton & Stump
• Opioid Hearings In NY AG's Suit Will Be Made Public
• How Orange Book Listings Affect Patent Density, Exclusivity
• J&J, Bayer, Teva Sued Over Eye Damage From Cyst Meds
• What I Learned As A Virtual Summer Associate
• Rising Star: Steptoe & Johnson's Vishal Gupta
• Sustainable Food Progress May Close Global Regulatory Gap
• Pandemic Sends Cannabis Sprout Cultivator Into Ch. 11
• Moderna Inks $1.5B Deal For COVID-19 Vaccine Candidate
• Fed. Circ. Urged To Undo Amgen's Win Over Cancer Drug IP
• Drugmakers Say Resellers Trying To Duck Bellwether Status
• W.Va. Doctor Illegally Prescribed Opioids, Jury Finds
• New Latham Partner Says It's 'Back To Biz' For Emerging Cos.
• Fluoride Risk Question Headed Back To EPA After Trial
• Mylan Asks Fed. Circ. To Undo PTAB Loss In Tecfidera Fight
• 'Questionable' Advice Lets Oxygen Mask Co. Dodge Contempt
• FDA Should Follow FTC For Influencer Health Post Rules
• Cooley Helps Atomwise Nab $123M For Drug Discovery Tech
• Tenn. DAs' Sackler Claims Still Blocked By Purdue Ch. 11
• Coronavirus Regulations: A State-By-State Week In Review
• Ex-Theranos CEO's Criminal Trial Moved To 2021 Due To Virus
• FDA Pressed To Take E-Cigs Off Market During Pandemic
• Linklaters, Goodwin Steer Bayer's $425M Women's Health Bet
• Rising Star: Skadden's Laura Knoll
• Lesser-Known Litigation Funding Best Practices For Attorneys
• SEC Reaches Settlement With Accused COVID-19 Fraudster
• MEI Pharma Lied About Cancer Drug's Potential, Investor Says
• Lawyer Says Thalidomide Client's Claims Are Years Late
• Botox Maker's IP Win 'Threatens Public Health,' ITC Told
• Calif. Judge Finds Del. Law Shields Directors In Ch. 11 Suit
• Green Thumb Can't Halt Arkansas Rival's Medical Pot License
• Ariz. Judge Tosses Challenge To Legal Pot Ballot Initiative
• Allergan Says Breast Implant MDL Claims Are Preempted
• Opioid Cos. Say NY Trial Shouldn't Be Livestreamed
• USD Law Dean Joins Perkins Coie's Emerging Cos. Group
• ADA Protects Lawyers With Disabilities, But We Must Do More
• Rising Star: Ropes & Gray's Zachary Blume
• Coronavirus Vaccine Contender CureVac Launches $200M IPO
• 9th Circ. Won't Rethink Rejected PetIQ Merger Challenge
• Kodak's $765M Loan Put On Hold Amid Stock Trading Scrutiny
• Legal Deserts Threaten Justice In Rural America
• Del. Judge Nixes Equity Panel In Biopharma Vivus' Ch. 11
• Trump's US-Made Drug Decree Sows Uncertainty In Industry
• Illumina Still Can't Get Injunction On Top Of $27M Patent Win
• COVID-19 IP Catch-Up: Remdesivir Drama & Jury Trial Regret
• Nev. Pot Regulators Sign Off On Settlement In License Fight
• JPML Consolidates Profemur Hip Implant Suits In Ark.
• Ex-NFL Players' Painkiller Suit Revived By 9th Circ.
• NAACP Wants Seat At Table In Purdue Bankruptcy Case
• HHS' $646M Virus Respirator Deal Faces Mounting Scrutiny
• Surgical Device Co. Says J&J Shouldn't Have Seized Products
• Tracking Arthrex At The Supreme Court
• K&L Gates Nabs Ex-Squire Patton Boggs Patent Pro In SF
• Coronavirus Q&A: Hogan Lovells' Medical Devices Director
• Gilead Can't Sit On Remdesivir Alternative, Activists Say
• Mich. Pot Regulator Recalls Joints After Worker Licked One
• Investors Pour $55M Into Diabetes-Focused Biotech Fractyl
• DLA Piper Adds Former US Rep. As Life Sciences Adviser
• Rising Star: Jones Day's Sarah A. Geers
• MD Who Gave Patient Info To Drug Rep Can't Nix Conviction
• Bayer, Merck Can't Be Pulled Back In Leg Amputation Suit
• Most Courts Follow 1st Circ. Generic-Delay Ruling's Standard
• White House Seeks To 'Onshore' Key Drug Manufacturing
• DEA Beats Discovery Subpoenas In Opioid MDL Bellwether
• Holistic Texas Biz Offered Bogus COVID-19 Tests, Feds Say
• 7th Circ. Says Class Objectors Must Repay Side Deals
• Judge Halts Calif. Pot Delivery Trial With Last-Minute Question
• Hemp Cos. Challenge Texas' Smokable Product Sale Ban
• 7th Circ. Says Chemist Can't Pin Firing On Caring For Grandpa
• AbbVie Inks $24M Deal With Calif. Regulators In Humira Case
• OECD To Consider Exemptions For New Tax System In Report
• Calif. County Can't Use Zoning To Seize Pot Plants, Court Says
• Retailers Face Uphill Fight For Cert. In Glumetza Price-Fix Suit
• Pharmacies Can't Dodge Ohio Opioid MDL's 2021 Bellwether
• Mass. Pot Shop Fined For Selling Faulty Vape Cartridges
• Analyzing Upward And Downward Trends In Legal Tech
• Paul Hastings Nabs Sidley Pair For FDA Regulatory Group
• Biogen Strikes Up To $2B Deal For Parkinson's Drug Collab
• What You Missed At PTAB: Contours Of IPR Institution Denial
• Bristol-Myers, Pfizer Win Fight Over Eliquis Patents
• Alleged Counterfeiter Seeks To Nix J&J Atty's Declarations
• Vivus Eases Equity Committee 'Death Trap' In Ch. 11 Plan
• DOJ Says Pot Study Fight Doesn't Belong In 9th Circ.
• Boehringer Dodges Sanctions In Florida Pradaxa Disputes
• Immunex Faces Skeptical Fed. Circ. In Antibody Patent Fight
• Colgate Retirees Want Judge's Final Word For ERISA Appeal
• Cannabis Operator TerrAscend Names New Top Lawyer
• Pa. Treasurer Slams Gilead's Coronavirus Treatment Pricing
• Lessons From Novartis' $678M Speaker Program Settlement
• EpiPen Buyers Lose Bid For Class Status In ERISA Suit
• Rite Aid Names Former Epstein Becker, LifePoint Atty As GC
• High Court Should Review Arthrex Case
• ABA's New Guidance On Litigation Funding Misses The Mark
• NJ Court Revives Suits Alleging J&J Talc Caused Cancer
• Cos. Should Track Microplastic Research And Regulations
• J&J Strikes $1B COVID-19 Vaccine Agreement With The Feds
• Adventist Rips Dismissal Bid In $57M PPE 'Conspiracy' Case
• 9th Circ. Rejects DOJ's Quick Appeal In Bid To End FCA Suit
• Bankrupt Whistleblower Can Sue Medical Co. In Kickback Row
• SEC Said To Be Probing Kodak Stock Spike After Gov't Loan
• More Finance Tools Go Hand-In-Hand With Larger SPAC Deals
• Ex-Rep. Collins Wants Sentence Delayed 3rd Time Over Virus
• 7th Circ. Told Chubb Unit Must Cover Lab's $3.3M TCPA Deal
• NY Doc Must Face Consumer Fraud Claim In Med Mal Suit
• Free COVID-19 Tests Are Not Kickbacks, HHS Watchdog Says
• Coronavirus Regulations: A State-By-State Week In Review
• Mass. Pot Regulator Again Eases Restrictions On Vapes
• States Defend FDA's Abortion Pill Restrictions At 4th Circ.
• Aceto Shareholders Lose Last Shot At Lawsuit
• How Biologics Cos. Disparage Biosimilars And How To Stop It
• VC Funding For Pharma Declines After Patent Rule Changes
• Courts Are Right To Scrutinize Food Labeling Suits
• Restrictive Covenants In California After Ixchel Pharma
• Bayer Says Essure Settlement Deal In The Works
• 3 Firms Steer Pair Of Blank Check IPOs Raising $439M
• Mylan Fights To Invalidate Novartis Blood Transfusion IP
• What Firms Should Ask Before Hiring Attorneys From Gov't
• How Federal Patent Tutorial Video Influences Jurors
• 3 Developments As Trump Orders Lasting Telehealth Changes
• Sandoz Warns Fed. Circ. Enbrel Ruling Invites Patent Abuse
• Fed. Circ. Trims Bio-Rad IP Win, But $24M Verdict Stays
• No Evidence FDA Sabotaged $375K-A-Year Drug, Judge Says
• Fed. Circ. Stays Uniloc Case For Justices' Arthrex Ruling
• Calif. High Court Establishes Tougher Antitrust Pleading Rules
• Ex-Theranos CEO Wants Too Much Info, Prosecutors Say
• 4th Circ. Backs CBS In Pharmacist's Opioid Defamation Suit
• Top Product Liability Cases Of 2020: Midyear Review
• Latham Edges Peers In Blistering July For IPOs
• Full Fed. Circ. Won't Revisit Save Of Illumina DNA Patents
• Alsup Nixes Ex-MLB Pitcher's Suit, Hints At Sanctions
• Md. Lab Says Ex-Partners Held Virus Test Results Hostage
• The Top In-House Hires Of July
• The Ethics Of Using Chatbots For Legal Services
• FDA Approves CBD Drug For Seizures Linked To Rare Disease
• Latham, Wachtell Steer Varian's $16.4B Sale To Siemens Unit